Last reviewed · How we verify
NCT02501707
Echocardiography for RILI Prediction
trial in NSCLC in 15 participants. Terminated before completion.
12 September 2019
Quick facts
| Lead sponsor | Maastricht Radiation Oncology |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 25 April 2017 |
| Primary completion | 12 September 2019 |
| Estimated completion | 12 September 2019 |
| Sites | 2 locations across Netherlands |
Conditions studied
- NSCLC — all drugs for NSCLC →
Sponsor
Maastricht Radiation Oncology — full company profile →
Who can join
18 and older, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Severe radiation-induced lung injury (RILI) occurs in approximately 20% of the lung cancer patients, who are treated with curative chemoradiation. In this study the investigators want to evaluate the prognostic value of baseline cardiac function assessed with echocardiography for prediction of RILI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02501707
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for NSCLC
Currently open trials in the same condition.
- NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
- NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
- NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting
Other Maastricht Radiation Oncology trials
Trials by the same sponsor.
- NCT07501845 — Registry Maastro Applicator · recruiting
- NCT07004582 — Lab Research Using Mini-tumors to Study Prostate Cancer Treatments · not yet recruiting
- NCT06024941 — Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer · Phase 2 · withdrawn
- NCT05182437 — Precision Radiation Treatment for Epilepsy (PRECISION) · NA · active not recruiting
- NCT02432417 — The Addition of Chloroquine to Chemoradiation for Glioblastoma, · Phase 2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02501707 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maastricht Radiation Oncology
- Last refreshed: 4 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02501707.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing